Leonteq Securities’s BridgeBio Pharma BBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$363K Buy
5,513
+1,500
+37% +$117K 0.01% 389
2026
Q2
$299K Buy
4,013
+1,989
+98% +$139K 0.01% 497
2026
Q1
$150K Sell
2,024
-570
-22% -$41.3K 0.01% 649
2025
Q4
$198K Sell
2,594
-1,500
-37% -$98.5K 0.01% 670
2025
Q3
$213K Buy
4,094
+3,810
+1,342% +$186K 0.01% 596
2025
Q2
$12.3K Sell
284
-370
-57% -$13.5K ﹤0.01% 1038
2025
Q1
$22.8K Sell
654
-3,778
-85% -$127K ﹤0.01% 965
2024
Q4
$122K Sell
4,432
-1,086
-20% -$28.1K 0.01% 645
2024
Q3
$140K Sell
5,518
-2,551
-32% -$67K 0.01% 557
2024
Q2
$204K Buy
8,069
+1,443
+22% +$39.5K 0.01% 483
2024
Q1
$205K Buy
+6,626
New +$225K 0.02% 494

Other funds holding BBIO

Leonteq Securities's BBIO Position: Q3 2026 in Review

Leonteq Securities increased its BridgeBio Pharma (BBIO) stake by 37% in Q3 2026, buying an estimated $117K and bringing the position to 5,513 shares worth $363K. The position accounts for 0.01% of the portfolio, ranked #389.

Leonteq Securities first reported a position in BBIO in Q1 2024 and has held it in 11 quarters since. 465 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.

  • Leonteq Securities held 5,513 shares of BridgeBio Pharma worth $363K as of Q3 2026.
  • Leonteq Securities bought 1,500 BridgeBio Pharma shares in Q3 2026, an estimated $117K.
  • BridgeBio Pharma made up 0.01% of Leonteq Securities's portfolio in Q3 2026, its #389 holding.
  • Leonteq Securities first reported a position in BridgeBio Pharma in Q1 2024 and has held it in 11 quarters since.
  • 465 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.

Based on Leonteq Securities's 13F filing for Q3 2026, filed 29 Oct 2026.